[Webmaster's clarification: for citations 1-10 see Legal Citations on movement disorders]

11. Abrams, Donald I., et al [2003]. Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med. 2003 Aug 19;139(4):258-66.

12. O'Shaughnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica); their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of the Medical and Physical Society of Bengal 1838-18; 40: 71-102, 421-61.

13. Ibid.

14. Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517-26. Muller-Vahl KR, et al. Cannabis in movement disorders. Forsch Komplementarmed. 1999 Oct;6 Suppl 3:23-7.

15. Amtmann D, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004 Mar-Apr;21(2):95-104.

16. Baker D, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000 Mar 2;404(6773):84-7.

17. Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuroendocrinol Lett. 2004 Feb- Apr;25(1-2):40-4.

18. Malec J, et al. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil. 1982 Mar;63(3):116-8.

19. Borg, J., Gershon, S. & Alpert, M. "Dose Effects of Smoking Marihuana on Human Cognitive and Motor Functions," Psychopharmacologia, 42, 211-218 (1975).

20. Dunn, M. & Ross, D. "The Perceived Effects of Marijuana on Spinal Cord Injured Males," Paraplegia, 12, 175 (1974).

21. Hanigan, W.C., Destree, R., Truong, X.T. "The Effects of Delta-9-THC on Human Spasticity," Journal of the American Society of Clinical Pharmacology & Therapeutics, 198 (Feb. 1986).

22. Manno, J. E., et.al. "Comparative Effects of Smoking Marihuana or Placebo on Human Motor & Mental Performance," Clinical Pharmacology & Therapeutics, 11:6, 808-815 (1970).

23. Meinck, H.M., et.al. "Effect of Cannabinoids on Spasticity and Ataxia in Multiple Sclerosis," Journal of Neurology, 236:120-22 (1989).

24. Petro, D. & Ellenberger, C. Jr.. "Treatment of Human Spasticity with Delta-9-Tetrahydrocannabinol," Journal of Clinical Pharmacology, 21:8&9, 413S-416S (1981).

25. Petro, D. "Marijuana as a Therapeutic Agent for Muscle Spasm or Spasticity," Psychosomatics,21:1, 81-85 (1980).

26. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol. 1995;35:607-634.

27. Abood ME and Martin BR. Molecular neurobiology of the cannabinoid receptor. Intl Rev Neurobiol. 1996;39:197-221.

28. Devane WA, Hanus L, Breur A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.

29. Barg J, Fride E, Hanus L, et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol. 1995;287:145-152.

30. Klein TW, Newton C and Friedman H. Cannabinoid receptors and immunity. Immunol Today. 1998; 797:225- 233.

31. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003 Oct;126(Pt 10):2191-202. Epub 2003 Jul 22.

32. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernandez-Ruiz J. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport. 2003 May 6;14(6):813-6.

33. Mechoulam R, Lichtman AH. Endocannabinoids. Stout guards of the central nervous system. Science. 2003 Oct 3;302(5642):65-7

34. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003;17(3):179-202.

35. McCarron RM, Shohami E, Panikashvili D, Chen Y, Golech S, Strasser A, Mechoulam R, Spatz M. Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). Acta Neurochir Suppl. 2003;86:271-5.

36. Sandyk, R., Consroe, P., Stern, L.Z. & Snider, S.R. "Effects of Cannabinoid in Huntington's Disease," Neurology, 36, 342 (1986).

37. Rodriguez De Fonseca F, et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res. 2001 Jan;3(1):23-35.

All rights reserved. Copyright pending 2008.